Durairaj C - Search Results

1

Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib.

Zheng J, Yu Y, Durairaj C, Diéras V, Finn RS, Wang DD. Zheng J, et al. Among authors: durairaj c. Target Oncol. 2021 Jan;16(1):69-76. doi: 10.1007/s11523-020-00771-5. Target Oncol. 2021. PMID: 33211314 Free PMC article.

2

Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.

Durairaj C, Ruiz-Garcia A, Gauthier ER, Huang X, Lu DR, Hoffman JT, Finn RS, Joy AA, Ettl J, Rugo HS, Zheng J, Wilner KD, Wang DD. Durairaj C, et al. Anticancer Drugs. 2018 Mar;29(3):271-280. doi: 10.1097/CAD.0000000000000589. Anticancer Drugs. 2018. PMID: 29360661 Free PMC article. Clinical Trial.

3

Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer.

Yu Y, Durairaj C, Shi H, Wang DD. Yu Y, et al. Among authors: durairaj c. J Clin Pharmacol. 2020 Feb;60(2):218-228. doi: 10.1002/jcph.1520. Epub 2019 Sep 6. J Clin Pharmacol. 2020. PMID: 31489639

4

Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment.

Guo C, Yu Y, Chakrabarti J, Piha-Paul SA, Moroose R, Plotka A, Shi H, Durairaj C, Wang DD, Wainberg ZA. Guo C, et al. Among authors: durairaj c. Br J Clin Pharmacol. 2022 Jul;88(7):3392-3403. doi: 10.1111/bcp.15294. Epub 2022 Mar 18. Br J Clin Pharmacol. 2022. PMID: 35236002 Free PMC article. Clinical Trial.

5

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors.

Durairaj C, Chakrabarti J, Ferrario C, Hirte HW, Babu S, Piha-Paul SA, Plotka A, Hoffman J, Shi H, Wang DD. Durairaj C, et al. Clin Pharmacokinet. 2021 Jul;60(7):921-930. doi: 10.1007/s40262-020-00983-y. Epub 2021 Mar 9. Clin Pharmacokinet. 2021. PMID: 33686631 Free PMC article. Clinical Trial.

6

Distribution, Metabolism, and Excretion of Gedatolisib in Healthy Male Volunteers After a Single Intravenous Infusion.

Houk BE, Alvey CW, Visswanathan R, Kirkovsky L, Matschke KT, Kimoto E, Ryder T, Obach RS, Durairaj C. Houk BE, et al. Among authors: durairaj c. Clin Pharmacol Drug Dev. 2019 Jan;8(1):22-31. doi: 10.1002/cpdd.615. Epub 2018 Sep 26. Clin Pharmacol Drug Dev. 2019. PMID: 30256541 Clinical Trial.

7

Ocular Pharmacokinetics.

Durairaj C. Durairaj C. Handb Exp Pharmacol. 2017;242:31-55. doi: 10.1007/164_2016_32. Handb Exp Pharmacol. 2017. PMID: 27787714

8

Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation.

Barañano DE, Kim SJ, Edelhauser HF, Durairaj C, Kompella UB, Handa JT. Barañano DE, et al. Among authors: durairaj c. Br J Ophthalmol. 2009 Oct;93(10):1387-90. doi: 10.1136/bjo.2009.157297. Epub 2009 Jul 23. Br J Ophthalmol. 2009. PMID: 19628498

9

Optimal sampling scheme for estimation of intraocular pressure diurnal curves in glaucoma trials.

Durairaj C. Durairaj C. Clin Pharmacokinet. 2015 Jan;54(1):95-105. doi: 10.1007/s40262-014-0183-9. Clin Pharmacokinet. 2015. PMID: 25227284

10

Mechanism - based translational pharmacokinetic - pharmacodynamic model to predict intraocular pressure lowering effect of drugs in patients with glaucoma or ocular hypertension.

Durairaj C, Shen J, Cherukury M. Durairaj C, et al. Pharm Res. 2014 Aug;31(8):2095-106. doi: 10.1007/s11095-014-1311-9. Epub 2014 Feb 19. Pharm Res. 2014. PMID: 24549827

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

23 results

Search Page

Filters